Letting cancer patients choose which genetic results they receive
Tests a choice of genetic results for people with cholangiocarcinoma, myeloma, colon or rectal cancer.
Plain-language title generated from the registry record
Registry title: Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Key facts
- Where
- St Louis, United StatesSee the site
Where in United States
- Washington University School of MedicineSt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT06340646
- Record updated
- 14 July 2026
- Original description
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.Read full original descriptionShow less
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.
Eligibility Criteria:; Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer; If diagnosed with multiple myeloma, must be African-American; If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis; At least 18 years old; Able to understand and willing to sign an IRB-approved written informed consent document.